Project description
An injectable, targeted, photoactivated therapy for congenital hyperinsulinism
The body’s cells are ‘fuelled’ by glucose produced by digestion of carbohydrates. When blood glucose levels rise, pancreatic beta cells release insulin which enables the body to absorb glucose. Too much or too little circulating blood glucose can cause problems. Congenital hyperinsulinism is a condition in newborns and infants caused by an overproduction of insulin, resulting in dangerously low blood glucose levels and hypoglycaemic brain injury. There is currently no therapy available without severe side effects, continuing health problems and tremendous economic burden. The EU-funded LightCure project intends to demonstrate that its injectable targeted photodynamic therapy can kill hyperfunctioning beta cells safely and effectively, enabling a normal life for babies and their families.
Objective
Congenital hyperinsulinism (CHI) is a group of rare diseases of newborns and infants with functionally defective nonneoplastic beta-cells that cause hypoglycemia and severe morbidity through oversecretion of insulin. CHI is a major cause of hypoglycemic brain injury with intellectual disability, epilepsy and cerebral palsy. As no registered causal therapy exists, management of CHI aims at increasing blood glucose levels causing severe side effects in all patients while life-threatening frequent hypoglycaemias remain. Removal of hyperfunctioning beta cells by pancreatectomy leads to insulin dependent diabetes mellitus (IDDM) and maldigestion of food, changing one disease for another with severe secondary morbidity. Management of CHI is choosing between evils and symptomatic management is partially effective in only some sub-types. CHI also represents a major burden for families, because of disability but also as a result of continuous monitoring and correction of glucose levels for many years, requiring permanent alertness. Health problems and economic decline occur in most parents. A normal life is not feasible for families with babies with CHI. LightCure consortium partners have demonstrated the feasibility of selectively targeting beta cells using exendin 4 (EX) labelled with a photosensitizer (700DX) specifically binding to beta cells. This photosensitizer can be activated by light of a certain wavelength and will produce radical oxygen species leading to cell damage, a principle called targeted photodynamic therapy (tPDT). In this project we will build on existing cutting-edge technology exclusively available to the consortium partners and perform human proof of concept studies demonstrating safety and efficacy of tPDT with EX700DX. We will deliver the proof-of-concept that after injection of EX700DX, minimally invasive tPDT leads to normalization of blood glucose levels avoiding morbidity, enabling a normal life for babies with CHI and their families.
Fields of science
Keywords
Programme(s)
Topic(s)
Funding Scheme
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinator
6525 GA Nijmegen
Netherlands